Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 1940-1949

  Jacobson, Lisa P ^a   Jenkins, F J ^b   Springer, G ^a   Munoz A ^a   Shah, K V ^a   Phair, J ^c   Zhang, Z F ^d   Armenian, H ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SEROCONVERSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; COHORT STUDIES; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; IMMUNE TOLERANCE; INCIDENCE; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; SARCOMA, KAPOSI;

EID: 0034092576     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315503     Document Type: Article

References (64)

1. 1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266: 1865-9.
2. 2. Su IJ, Hsu YS, Change YC, Wang IW. Herpesvirus-like DNA sequence in Kaposi's sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet 1995;345:722-3.
3. 3. Dupin N, Grandadam M, Calvez V, et al. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 1995;345:761-2.
4. 4. Huang YQ, Li JJ, Kaplan MH, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995;345:759-61.
5. 5. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. N Engl J Med 1995;332:1181-5.
6. 6. Boshoff C, Whitby D, Hatziioannou T, et al. Kaposi's-sarcoma associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 1995;345:1043-4.
7. 7. Smith MS, Bloomer C, Horvat R, Goldstein E, Casparian JM, Chandran B. Detection of human herpesvirus 8 DNA in Kaposi's sarcoma lesions and peripheral blood of human immunodeficiency virus positive patients and correlation with serologic measurements. J Infect Dis 1997;176:84-93.
8. 8. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among American, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996;2: 925-8.
9. 9. Regamey N, Cathomas G, Schwager M, Wernli M, Harr T, Erb P. High human herpesvirus 8 seroprevalence in the homosexual population in Switzerland. J Clin Microbiol 1998;36:1784-6.
10. 10. Rezza G, Lennette ET, Giuliani M, et al. Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. Int J Cancer 1998;77:361-5.
11. 11. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996;348:858-61.
12. 12. Grulich AE, Olsen SJ, Luo K, et al. Kaposi's sarcoma associated herpesvirus: a sexually transmissible infection? J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:387-3.
13. 13. Moore PS, Kingsley LA, Holmberg SD, et al. Kaposi's sarcoma associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 1996;10: 175-80.
14. 14. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346: 799-802.
15. 15. Melbye M, Cook PM, Hjalgrim H, et al. Risk factors for Kaposi's-sarcoma associated herpesvims (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer 1998;77:543-8.
16. 16. Renwick N, Halaby T, Weverling GJ, et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 1998;12:2481-8.
17. 17. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338:948-54.
18. 18. Schulz TF, Moore PS, Kaposi's sarcoma associated herpesvirus: a new human tumor virus, but how? Trends Microbiol 1999;7:196-200.
19. 19. Armenian HK, Hoover DR, Rubb S, et al. Composite risk score for Kaposi's sarcoma based on a case-control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population. Am J Epidemiol 1993;138: 256-65.
20. 20. Jacobson LP, Armenian HK. An integrated approach to the epidemiology of Kaposi's sarcoma. Curr Opin Oncol 1995;7:450-5.
21. 21. Detels R, Phair JP, Saah AJ, et al. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol (Japan) 1992;2:S11-19.
22. 22. Dudley J, Jin S, Hoover D, Metz S, Thackeray R, Chmiel J. The Multicenter AIDS Cohort Study: retention after 91/2 years. Am J Epidemiol 1995;142: 323-30.
23. 23. Kaslovv RA, Ostrow DC, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organisation, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-8.
24. 24. Renne R, Zhong W, Herndier B, et al. Lytic growth of Kaposi's sarcoma associated herpesvirus (human herpesvirus 8) in culture. Nat Med 1996; 2:342-6.
25. 25. Vu HN, Jenkins FW, Swerdlow SH, Locker J, Lotze MT. Pleural effusion as the presentation for primary effusion lymphoma. Surgery 1998;123: 589-91.
26. 26. Kingsley LA, Zhou SYJ, Bacellar H, et al. Temporal trends in human immunodeficiency virus type 1 seroconversion 1984-1989: a report from the Multicenter AIDS Cohort Study (MACS). Am J Epidemiol 1991;134: 331-9.
27. 27. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol 1990;55:173-86.
28. 28. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry 1993;14:307-17.
29. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
30. 30. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-20.
31. 31. Anonymous. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855-67.
32. 32. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41:1-19.
33. 33. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-1503.
34. 34. Graham NMH, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-1 seropositive homosexual men in the Multicenter AIDS Cohort Study (MACS), 1987-1989. J Acquir Immune Defic Syndr 1991;4:267-76.
35. 35. Graham NMH, Jacobson LP, Kuo V, Chmiel JS, Morgenstern H, Zucconi SL. Access to therapy in the Multicenter AIDS Cohort Study, 1989-1992. J Clin Epidemiol 1994;47:1003-12.
36. 36. Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996;335: 233-41.
37. 37. Renne R, Lagunoff M, Zhong W, Ganem D. The size and conformation of Kaposi's sarcoma associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 1996;70:8151-4.
38. 38. Micallef INM, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998;22:981-7.
39. 39. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infeetion and immunosuppression. Transplantation 1996;62:370-5.
40. 40. Quinnan GV Jr, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 1984;252:72-77.
41. 41. Evans AS, Kaslow RA, eds. Viral infections of humans: epidemiology and control. 4th ed. New York, NY: Plenum, 1997.
42. 42. Corey L, Spear PG. Medical progress: infections with herpes simplex viruses (1). N Engl J Med 1986;314:686-91.
43. 43. Corey L, Spear PG. Medical progress: infections with herpes simplex viruses (2). N Engl J Med 1986;314:749-57.
44. 44. Corey L. First-episode, recurrent, and asymptomatic herpes simplex infections. J Am Acad Dermatol 1988;18:169-72.
45. 45. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983;98:958-72.
46. 46. Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998;17:1161-6.
47. 47. Green M, Cacciarelli TV, Mazariegos GV, et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998;66:1641-4.
48. 48. Savoie A, Perpête C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus infected lymphocytes in the peripheral blood and pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-22.
49. + cytotoxic T lymphocyte responses (CTL) to lytic proteins of human herpesvirus 8 (HHV-8). J Acquir Immune Defic Syndr 1999;21(Suppl):A11.
50. 50. Harwood AR, Osoba D, Hofstader SL, et al. Kaposi's sarcoma in recipients of renal transplants. Am J Med 1979;67:75965.
51. 51. Muñoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993;137:423-38.
52. 52. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995;92:4838-42.
53. 53. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-86.
54. 54. Ensoli B, Nakamura S, Salahuddin SZ, et al. AIDS Kaposi sarcoma derived cells express cytokines with autocrine and paracrine growth effects. Science 1989;243:223-6.
55. 55. Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS Kaposi's sarcoma spindle cells. J Clin Invest 1995;95:1723-34.
56. + T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus 1 Tat protein: an immune response to human herpesvirus-8 infection? Blood 1998;91:956-67.
57. 57. Gallo RC. Some aspects of the pathogenesis of HIV-1 associated Kaposi's sarcoma. J Natl Cancer Inst 1998;23:55-57.
58. 58. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-680.
59. 59. Fiorelli V, Barillari G, Toschi E, et al. IFN-γ induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogens. J Immunol 1999;162:1165-70.
60. 60. Kelly GD, Ensoli B, Gunthel CJ, Offermann MK. Purified Tat induces inflammatory response genes in Kaposi's sarcoma cells. AIDS 1998;12: 1753-61.
61. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
62. 62. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
63. 63. Lebbé C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998;12:F45-49.
64. 64. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1 infected individuals: Multicenter AIDS Cohort study. J Acquir Immune Defic Syndr 1999;21:S34-41.